Sanctuary Advisors’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SCV
SCM
FFM
TECP
ACM
SL
CC
VCM
Sanctuary Advisors's IKT Position: Q1 2026 in Review
Sanctuary Advisors sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 12,539 shares — an estimated $25.7K sold.
Sanctuary Advisors first reported a position in IKT in Q4 2025 and held it in 1 quarter. The position peaked at $25.7K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.
- Sanctuary Advisors reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
- Sanctuary Advisors sold 12,539 Inhibikase Therapeutics shares in Q1 2026, an estimated $25.7K.
- Sanctuary Advisors first reported a position in Inhibikase Therapeutics in Q4 2025 and held it in 1 quarter.
- Sanctuary Advisors's Inhibikase Therapeutics position peaked at $25.7K in Q4 2025.
- 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.
Based on Sanctuary Advisors's 13F filing for Q1 2026, filed 5 May 2026.